相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Adjusting for Treatment Switching in Oncology Trials: A Systematic Review and Recommendations for Reporting
Thomas R. Sullivan et al.
VALUE IN HEALTH (2020)
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
Youn H. Kim et al.
LANCET ONCOLOGY (2018)
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
H. Miles Prince et al.
LANCET (2017)
Adjusting for treatment switching in randomised controlled trials - A simulation study and a simplified two-stage method
Nicholas R. Latimer et al.
STATISTICAL METHODS IN MEDICAL RESEARCH (2017)
Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality
Shigeo Fuji et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
A GUIDE TO ADJUSTING SURVIVAL TIME ESTIMATES TO ACCOUNT FOR TREATMENT SWITCHING IN RANDOMISED CONTROLLED TRIALS
N. R. Latimer et al.
VALUE IN HEALTH (2013)
Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value Sets
Ben van Hout et al.
VALUE IN HEALTH (2012)
分享论文
